Discovery research robustness

Microarrays have become robust, reliable research tools that enable researchers to screen for a multitude of parameters using minimal amounts of sample material. The acceptance of protein microarrays is growing constantly they have already been demonstrated to be useful tools in disease-related biomarker discovery. In addition, protein microarrays have been introduced into clinical trials in order to investigate the potential adverse effects of drug candidates. Depending on the number of validated disease-specific biomarkers, as well as on their therapeutic relevance, such assays are performed either on a protein microarray or a bead-based platform. 

Although the gentle reaction conditions and apparent sustainability of this oxidation process provide encouraging indications of likely success, the long-known cleanly reactive MTO catalyst has not previously been exploited. Since its discovery in 1978 by Beattie and Jones [38], the unique nature of MTO has stimulated enormous amounts of research, with contributions from many laboratories. Most notable was the discovery by Herrmann and his coworkers that MTO is a superb oxidation catalyst when used with H2O2 [39,40]. MTO is soluble in most solvents and stable. Although many compounds of the formula RReOs exist, MTO is unique in being the most robust and active [41 3]. 

---